- Home
- VRSN vs ROIV Comparison
VRSN vs ROIV Comparison
Compare VRSN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRSN | ROIV |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 20.7B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRSN | ROIV |
|---|---|---|
| Price | $275.37 | $28.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $317.67 | $28.94 |
| AVG Volume (30 Days) | 761.5K | ★ 4.3M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.24 | N/A |
| Revenue | ★ $1,656,600,000.00 | $29,053,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $5.37 | $744.61 |
| P/E Ratio | $44.21 | ★ N/A |
| Revenue Growth | ★ 6.37 | N/A |
| 52 Week Low | $209.34 | $10.58 |
| 52 Week High | $310.60 | $30.33 |
Technical Indicators
Market Signals| Indicator | VRSN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 53.80 |
| Support Level | $260.30 | $27.00 |
| Resistance Level | $287.15 | $30.26 |
| Average True Range (ATR) | 7.36 | 0.91 |
| MACD | -0.70 | -0.04 |
| Stochastic Oscillator | 87.49 | 51.76 |
Price Performance
Historical ComparisonAbout VRSN VeriSign Inc.
Verisign is an operator of critical infrastructure within the domain name system, or DNS. As the registry for some of the world's most popular TLDs, .com and .net, Verisign directs DNS resolvers to the appropriate registry where IP addresses are stored. Verisign's control over its TLDs is regulated by ICANN and the NTIA and are subject to contract renewal every six years. The company generates revenue through annual subscriptions allowing customers to use .com and .net as their TLD of choice for their respective websites.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.